Health sciences group PreveCeutical Medical Inc (CSE: PREV, OTCQB: PRVCF) said shares began trading on the OTCQB Venture Marketplace in the US on September 15.
The index is for early-stage and developing United States and international companies.
“We are extremely pleased to be able to upgrade to quote on the OTCQB.
"This listing will enable us to expand our US shareholder base as well as offer the company’s existing US shareholders a more transparent and efficient platform to obtain quotes and trade PreveCeutical securities," said PreveCeutical’s chairman and chief executive Stephen Van Deventer.
The group is developing innovative preventive therapies using organic and nature identical products and currently has five research and development programs.
These are dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions.
The group also sells CELLB9, an immune system booster.